Identity
- Security key
- 20080
- Ticker
- PGEN
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2013-08-08
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- PGEN
Detail
Enriched 2026-08-14 20:47
- Market cap
- $2,452,541,441.95
- Shares outstanding (class)
- 356,510,980
- Shares outstanding (weighted)
- 358,035,247
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 47
- Location
- GERMANTOWN, MD
- Homepage
- http://www.precigen.com
- Description
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.